We are live on ! Find out more
RGNX icon

Regenxbio
RGNX

108 hedge funds and large institutions have $718M invested in Regenxbio in 2017 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 10

107% more call options, than puts

Call options by funds: $13.1M | Put options by funds: $6.3M

21% more funds holding

Funds holding: 89 → 108 (+19)

2% more capital invested

Capital invested by funds: $704M → $718M (+$13.6M)

0.14% more ownership

Funds ownership: 69.15% → 69.29% (+0.14%)

12% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 34

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
108
Holders Change
+19
Holders Change %
+21.35%
% of All Funds
2.45%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
29
Increased
30
Reduced
34
Closed
10
Calls
$13.1M
Puts
$6.3M
Net Calls
+$6.75M
Net Calls Change
+$5.12M

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$23.2M
2
Citadel Advisors
Citadel Advisors
Florida
+$11.4M
3
State Street
State Street
Massachusetts
+$8.41M
4
DM
Deerfield Management
New York
+$7.72M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$7.68M

Top Sellers

Rank Fund Capital Flow
1
BCPEM
Bain Capital Public Equity Management
Massachusetts
-$23.8M
2
BlackRock
BlackRock
New York
-$21.6M
3
FCM
Farallon Capital Management
California
-$13.7M
4
GC
GMT Capital
Georgia
-$12.5M
5
RG
Redmile Group
California
-$7.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
26
Schonfeld Strategic Advisors
New York
$5.28M +$559K +18,567 +13%
Goldman Sachs
27
Goldman Sachs
New York
$5.04M -$371K -12,301 -7%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$4.55M -$49.7K -1,648 -1%
Charles Schwab
29
Charles Schwab
California
$4.26M +$171K +5,678 +5%
Two Sigma Investments
30
Two Sigma Investments
New York
$4.25M +$2.01M +66,775 +109%
Millennium Management
31
Millennium Management
New York
$3.2M +$2.9M +96,358 New
Bank of America
32
Bank of America
North Carolina
$3.19M +$802K +26,624 +39%
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$2.74M +$2.48M +82,322 New
Citigroup
34
Citigroup
New York
$2.67M +$732K +24,285 +43%
Hudson Bay Capital Management
35
Hudson Bay Capital Management
Connecticut
$2.49M +$1.66M +55,000 +275%
TCIM
36
TIAA CREF Investment Management
New York
$2.24M -$76.4K -2,537 -4%
ACM
37
Atika Capital Management
New York
$2M +$904K +30,000 +100%
Victory Capital Management
38
Victory Capital Management
Texas
$1.99M +$340K +11,300 +23%
RA
39
Royce & Associates
New York
$1.96M +$1.78M +59,000 New
JGC
40
J. Goldman & Co
New York
$1.86M -$575K -19,089 -25%
Mirae Asset Global Investments
41
Mirae Asset Global Investments
South Korea
$1.79M -$55.3K -1,837 -3%
TA
42
Teachers Advisors
New York
$1.66M -$5.6K -186 -0.4%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$1.44M -$19.3K -640 -1%
Swiss National Bank
44
Swiss National Bank
Switzerland
$1.42M – – –
MCM
45
McKinley Capital Management
Alaska
$1.39M +$874 +29 +0.1%
MWNA
46
Marshall Wace North America
New York
$1.34M +$1.21M +40,251 New
HCM
47
Highbridge Capital Management
New York
$1.33M +$1.21M +40,000 New
Squarepoint
48
Squarepoint
New York
$1.18M +$1.07M +35,421 New
Wells Fargo
49
Wells Fargo
California
$1.18M -$275K -9,117 -21%
GH
50
GAM Holding
Switzerland
$1.17M +$545K +18,100 +106%
1
2
3 4 5

RGNX Hedge Fund Activity: Q4 2017 in Review

108 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q4 2017, worth a combined $718M — up 1.9% from $704M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new RGNX positions and 10 closed out — a net gain of 19 holders — while 30 added to existing stakes and 34 trimmed.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $23.2M. The largest seller was Bain Capital Public Equity Management, exiting entirely with an estimated $23.8M sold.

  • 108 institutional investors held Regenxbio (RGNX) as of Q4 2017, up from 89 in Q3 2017.
  • Funds reported $718M of Regenxbio stock for Q4 2017, up 1.9% quarter-over-quarter.
  • 29 funds opened new Regenxbio positions in Q4 2017 and 10 closed out, a net change of +19 holders.
  • The largest Regenxbio buyer in Q4 2017 was PFM Health Sciences, an estimated $23.2M added.
  • The largest Regenxbio seller in Q4 2017 was Bain Capital Public Equity Management, an estimated $23.8M sold.

Based on aggregated 13F filings for Q4 2017.